Cheryl Pugh

2.0k total citations · 1 hit paper
17 papers, 1.1k citations indexed

About

Cheryl Pugh is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Cheryl Pugh has authored 17 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 3 papers in Cancer Research. Recurrent topics in Cheryl Pugh's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (5 papers). Cheryl Pugh is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Diagnosis and Treatment (5 papers) and Lung Cancer Research Studies (5 papers). Cheryl Pugh collaborates with scholars based in United Kingdom, Germany and Australia. Cheryl Pugh's co-authors include Matthew Nankivell, Richard Stephens, Mahesh Parmar, Corinne Faivre‐Finn, Ruth E. Langley, P. Mulvenna, Rachael Barton, Barbara Moore, N. Bayman and Tanya Holt and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Cheryl Pugh

16 papers receiving 1.1k citations

Hit Papers

Dexamethasone and supportive care with or without whole b... 2016 2026 2019 2022 2016 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial
    2016 453 citations P. Mulvenna, Matthew Nankivell et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Cheryl Pugh United Kingdom 10 970 619 222 124 102 17 1.1k
L. Trodella Italy 14 469 0.5× 353 0.6× 122 0.5× 192 1.5× 140 1.4× 58 826
N. Bayman United Kingdom 15 753 0.8× 456 0.7× 187 0.8× 131 1.1× 147 1.4× 48 950
P.A. Burt United Kingdom 17 1.0k 1.1× 810 1.3× 110 0.5× 242 2.0× 117 1.1× 48 1.4k
Astrid Dalhaug Norway 16 435 0.4× 386 0.6× 143 0.6× 212 1.7× 80 0.8× 70 715
R. Corre France 17 816 0.8× 541 0.9× 149 0.7× 102 0.8× 42 0.4× 88 1.0k
John P. Lamond United States 14 798 0.8× 258 0.4× 449 2.0× 132 1.1× 121 1.2× 29 994
Nicolas Martin France 14 385 0.4× 244 0.4× 122 0.5× 140 1.1× 58 0.6× 50 711
Shimao Fukai Japan 16 820 0.8× 442 0.7× 72 0.3× 208 1.7× 105 1.0× 48 1.0k
Radka Lohynská Czechia 14 401 0.4× 339 0.5× 180 0.8× 127 1.0× 92 0.9× 37 560
Rachit Kumar United States 17 326 0.3× 354 0.6× 48 0.2× 177 1.4× 119 1.2× 50 724

Countries citing papers authored by Cheryl Pugh

Since Specialization
Citations

This map shows the geographic impact of Cheryl Pugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl Pugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl Pugh more than expected).

Fields of papers citing papers by Cheryl Pugh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl Pugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl Pugh. The network helps show where Cheryl Pugh may publish in the future.

Co-authorship network of co-authors of Cheryl Pugh

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl Pugh. A scholar is included among the top collaborators of Cheryl Pugh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl Pugh. Cheryl Pugh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Gray, Emma, Susan C. Scott, Guy Peryer, et al.. (2023). Enhancing involvement of people with multiple sclerosis in clinical trial design. Multiple Sclerosis Journal. 29(9). 1162–1173. 8 indexed citations
2.
Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2016). Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. The Lancet. 388(10055). 2004–2014. 453 indexed citations breakdown →
3.
Richman, Susan D., Richard Adams, Philip Quirke, et al.. (2015). Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology. 69(1). 35–41. 16 indexed citations
4.
Mulvenna, P., Matthew Nankivell, Rachael Barton, et al.. (2015). Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061).. Journal of Clinical Oncology. 33(15_suppl). 8005–8005. 21 indexed citations
5.
6.
Shiu, Kai‐Keen, Tim Maughan, Richard H. Wilson, et al.. (2013). FOCUS4: A prospective molecularly stratified, adaptive multicenter program of randomized controlled trials for patients with colorectal cancer (CRC).. Journal of Clinical Oncology. 31(15_suppl). TPS3645–TPS3645.
7.
8.
Wasan, Harpreet, Richard Adams, Richard H. Wilson, et al.. (2012). Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial.. Journal of Clinical Oncology. 30(4_suppl). 536–536. 10 indexed citations
9.
Sebag‐Montefiore, David, et al.. (2012). OC-0219 THE MRC CR07 TRIAL NCIC CO16 TRIAL AFTER A MEDIAN FOLLOW UP OF 8 YEARS. Radiotherapy and Oncology. 103. S85–S85. 4 indexed citations
10.
Hatton, M., Matthew Nankivell, Stephen Falk, et al.. (2010). Induction Chemotherapy and Continuous Hyperfractionated Accelerated Radiotherapy (CHART) for Patients With Locally Advanced Inoperable Non–Small-Cell Lung Cancer: The MRC INCH Randomized Trial. International Journal of Radiation Oncology*Biology*Physics. 81(3). 712–718. 26 indexed citations
11.
12.
Muers, Martin F., Richard Stephens, P.M. Fisher, et al.. (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. The Lancet. 371(9625). 1685–1694. 177 indexed citations
13.
14.
15.
Hopwood, Penelope, Matthew Nankivell, Cheryl Pugh, et al.. (2007). Impact of pre-operative chemotherapy on the quality of life (QL) of patients with resectable non-small cell lung cancer (NSCLC): Experience from the MRC LU22/NVALT/EORTC 08012 multicentre randomised trial. Journal of Clinical Oncology. 25(18_suppl). 9020–9020. 1 indexed citations
16.
17.
Nicolson, M., David Gilligan, I. E. Smith, et al.. (2007). Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): First results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial. Journal of Clinical Oncology. 25(18_suppl). 7518–7518. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by L. Trodella Breakdown of academic impact, for papers by N. Bayman Breakdown of academic impact, for papers by P.A. Burt Breakdown of academic impact, for papers by Astrid Dalhaug Breakdown of academic impact, for papers by R. Corre Breakdown of academic impact, for papers by John P. Lamond Breakdown of academic impact, for papers by Nicolas Martin Breakdown of academic impact, for papers by Shimao Fukai Breakdown of academic impact, for papers by Radka Lohynská Breakdown of academic impact, for papers by Rachit Kumar
Rankless by CCL
2026